Cantor Fitzgerald’s Prelude Therapeutics PRLD Stock Holding History

Cantor Fitzgerald’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-211,859	Closed	-$171K	–	501
2025 Q2	$171K	Buy	+211,859	New	+$183K	﹤0.01%	322

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Cantor Fitzgerald's PRLD Position: Q3 2025 in Review

Cantor Fitzgerald sold out of Prelude Therapeutics (PRLD) in Q3 2025, closing a stake of 211,859 shares — an estimated $171K sold.

Cantor Fitzgerald first reported a position in PRLD in Q2 2025 and held it in 1 quarter. The position peaked at $171K in Q2 2025. 47 funds tracked by Wall St. Rank hold PRLD as of Q3 2025.

Cantor Fitzgerald reported no remaining Prelude Therapeutics position as of Q3 2025 after selling out during the quarter.
Cantor Fitzgerald sold 211,859 Prelude Therapeutics shares in Q3 2025, an estimated $171K.
Cantor Fitzgerald first reported a position in Prelude Therapeutics in Q2 2025 and held it in 1 quarter.
Cantor Fitzgerald's Prelude Therapeutics position peaked at $171K in Q2 2025.
47 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2025.

Based on Cantor Fitzgerald's 13F filing for Q3 2025, filed 14 Nov 2025.